About

Service

Advantage

Quarkmed Dynamics

Featured Services

Human Resources

Mail System

CTMS System

中EN

Quarkmed Dynamics

Quarkmed will keep moving forward, paying attention to hot topics in the industry, discussing the latest developments in the industry, and working with enterprises to promote new progress in medicine.
Partial Cooperative ClientsQuarkmed NewsTeam Style
Home>Quarkmed Dynamics

Nectin-4 Radiopharmaceutical Development Hits the Accelerator!

2026-05-20

Target Introduction RNA and Protein Expression of Nectin-4 (proteinatlas.org) Overview: Nectin-4 (Neural cell adhesion molecule-related molecule 4), also known as Poliovirus Receptor-Related Protein 4 (PVRL4), is a type I transmembrane glycoprotein belonging to the Nectin subfamily of the immunoglobulin superfamily (IgSF). Encoded by the PVRL4 gene located on chromosome 1q23.3, its mature protein ...

MORE
202026-05

In-Depth Analysis: The First B7-H3 Radiopharmaceutical Omburtamab's Failed Bid for FDA Approval

B7-H3: An IntroductionAs a hot target in tumor immunotherapy, B7-H3 has not only attracted fierce competition among multiple ADC (Antibody-Drug Conjugate) developers but has also garnered significant ...

202026-05

Quarkmed Invites You to SNMMI 2026: Exploring the Future of Nuclear Medicine

The 2026 SNMMI Annual Meeting will be held from May 30 to June 2, 2026, at the Los Angeles Convention Center. Quarkmed will be exhibiting at the event, and we warmly invite you to visit us at Booth 28...

192026-05

One Article to Understand the R&D Status of CXCR4-Targeted Nuclear Drugs!

CXCR4 Target and Related Nuclear Drugs IntroductionThe interactions between the CXCR4 receptor, its ligand CXCL12, and other interacting molecules, along with their roles in cell signaling. Image adap...

192026-05

How to Get Started with 225Ac Nuclear Drugs? This One is Enough!

Nuclear Drug: 225Ac-ch806Journal of Nuclear Medicine 2024; 00:1–7 This article analyzes the key data of preclinical studies on 225Ac nuclear drugs with examples. Published in December 2024 in th...

202026-04

Heyue Pharma: The Professional Choice for On-site Management of Radiopharmaceutical Clinical Trials

Heyue Pharma (hereinafter referred to as "Heyue"), a professional SMO under QuarkMed specializing in the field of radiopharmaceuticals, has been operating steadily for many years, consistently deliver...

232026-01

A New Breakthrough in B7-H3-Targeted Therapy: Frontier Exploration from ADCs to Radiopharmaceuticals

The B7-H3 ADC ExperienceIn 2020, Dr. Tongtong Xue co-founded Yilian Biology alongside a team of seasoned industry experts. As an innovative biotech company focused on the research and development of t...

232026-01

Actinium-225: The "Alpha Warrior" Ushering in a New Era of Radiopharmaceutical Therapy

An Introduction to the Actinium-225 Nuclide and the ACTION-1 StudyAlpha-emitting radiopharmaceuticals utilize radionuclides that emit alpha particles, such as Radium-223 ([²²³Ra]), Acti...

302025-09

Happy Hour - Gathering at EANM 2025

As Europes largest nuclear medicine academic event, EANM brings together experts, scholars, and industry partners from around the world annually to discuss the latest developments and future trends in...

302025-09

Quarkmed has won the title of "Best Partner" / "Best Partner Award"

Recently, Quarkmed was awarded the "Best Partner" award by Jingxin Pharmaceutical for its outstanding professional performance and efficient project execution in the Phase III clinical trial collabora...

12

Contact Us

010-86469979

Address：Ping An Fortune Center, Lize Financial Business District of Beijing

Follow the Wechat official account

Follow the Wechat official account